<DOC>
	<DOCNO>NCT02228382</DOCNO>
	<brief_summary>The purpose study fulfill post-authorization commitment make Pfizer European Medicines Agency provide additional safety efficacy data approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patient high unmet medical need , include 75 Chronic Phase , Accelerated Phase Blast Phase patient fourth later line treatment setting ( i.e. , treatment least 3 Tyrosine Kinase Inhibitors ) .</brief_summary>
	<brief_title>Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Confirmed Philadelphia Chromosome positive Chronic Myeloid Leukemia Confirmed BCRABL1 ( Abelsonbreak point cluster ) Positive Philadelphia Chromosome negative Chronic Myeloid Leukemia ( initial diagnosis ) . Prior treatment 1 tyrosine kinase inhibitor drug ( imatinib , dasatinib and/or nilotinib ) Philadelphia Chromosome positive Chronic Myeloid Leukemia ( CML ) . Any Chronic Myeloid Leukemia disease phase , long patient unable receive treatment imatinib , dasatinib and/or nilotinib reason . Participation clinical study involve investigational drug ( ) within 14 day within 3 halflives drug level blood ( whichever longer ) prior first dose bosutinib . Prior treatment bosutinib . Prior treatment ponatinib . Known T315I V299L mutation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelogenous</keyword>
	<keyword>Chronic</keyword>
	<keyword>BC-ABL Positive</keyword>
</DOC>